特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
930644

生物医薬品CMOの世界市場:製品の種類別、地域別、国別の分析:機会と予測

Global Biopharmaceutical CMO Market - Analysis By Product Type, By Region, By Country : Opportunities and Forecast - By Region, By Country

出版日: | 発行: Azoth Analytics | ページ情報: 英文 130 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
生物医薬品CMOの世界市場:製品の種類別、地域別、国別の分析:機会と予測
出版日: 2020年03月31日
発行: Azoth Analytics
ページ情報: 英文 130 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

生物医薬品の製造受託機関 (CMO) の市場は、2019年の時点で132億9,629万米ドルの規模を有しています。医療部門への投資は世界各国で拡大しており、各種のウイルスが健康に及ぼす影響に対する人々の認識も高まっていることから、英国、ノルウェー、デンマーク、スイスなど医療制度が整った国々を中心に生物医薬品CMO市場の成長は加速する見通しです。こうしたなか主要なCMOは、製薬会社との提携関係を強化し、買収や合併などの動きを活発化させることで市場シェアの拡大を目指すと見られています。

当レポートは、世界の生物医薬品CMO市場を調査し、戦略的提言を行うとともに、製品や市場規模の予測、製品のタイプ別、地域別の分析、競合状況、主要企業の分析などの情報を提供しています。

目次

第1章 調査方法とエグゼクティブサマリー

  • 調査方法
  • エグゼクティブサマリー

第2章 戦略的な提言

  • 品質と信頼性の向上に注力
  • 組織内部の要因に対する投資に注力

第3章 世界の生物医薬品CMO市場:製品の将来展望

第4章 世界の生物医薬品CMO市場:市場規模と予測

  • 市場規模(金額ベース、2015年-2025年)

第5章 世界の生物医薬品CMO市場:製品の種類別の内訳

  • 競争シナリオ:製品の種類別
    • 微生物:市場規模と予測(2015年-2025年)
    • その他:市場規模と予測(2015年-2025年)

第6章 世界の生物医薬品CMO市場:地域分析

  • 競争シナリオ :地域別

第7章 北米の生物医薬品CMO市場: 製品の種類別 (2015年-2025年)

  • 北米の生物医薬品CMO市場:市場規模と予測(金額ベース、2015年-2025年)
  • 市場区分:製品の種類別(微生物、その他)
  • 国別分析
  • 市場機会チャート:国別(金額ベース、2025年)
  • 競争シナリオ :国別
  • 米国

第8章 欧州の生物医薬品CMO市場: 製品の種類別 (2015年-2025年)

  • ドイツ
  • スイス
  • デンマーク

第9章 アジア太平洋の生物医薬品CMO市場: 製品の種類別 (2015年-2025年)

  • 中国
  • 日本
  • 韓国

第10章 世界のバイオ医薬品CMO 市場の力学

  • 成長促進要因
  • 成長阻害要因
  • 動向

第11章 市場の魅力

  • 市場の魅力チャート: 製品の種類別(2025年)
  • 市場の魅力チャート:地域別(2025年)

第12章 戦略的分析と競合情勢

  • SWOT分析
  • 技術革新を担っている主な企業と合併・買収
  • 市場シェア分析

第13章 会社分析

  • Lonza
  • Boehringer Ingelheim
  • Samsung Biologics
  • Wuxi Biologics
図表

List of Figures

  • Figure 1: Global Bio CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 2: Global Biologics market Outlook, 2012, 2016, 2021 (In Billion )
  • Figure 3: Global Biologics market Outlook, By Countries, 2019 (In Billion)
  • Figure 4: Global Healthcare Expenditure, 2012-2016 (In Trillion)
  • Figure 5: Global Biopharmaceutical CMO Market, By Product Type, 2019, 2025
  • Figure 6: Global Biopharmaceutical CMO Market - By Microbial, By Value (USD Million), 2015-2025
  • Figure 7: Global Biopharmaceutical CMO Market - By Others, By Value (USD Million), 2015-2025
  • Figure 8: Global Biopharmaceutical CMO Market, By Region, 2019, 2025
  • Figure 9: North America Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 10: North America GDP, 2014-2017 (USD Trillion)
  • Figure 11: North America GDP, By Select Country, 2018 (USD Trillion)
  • Figure 12: North America Healthcare Cost Per Capita, By Select Country, 2018 (USD)
  • Figure 13: Number of Citizen 65 years and above, USA and Canada in Million 2018
  • Figure 14: Number of Citizen 65 years and above, USA and Canada in Million 2060
  • Figure 15: North America Prevalence of Gynecological Disorders (2014-2016)
  • Figure 16: Total Number of People with North America Neglected Tropical Disorders (2014-2016)
  • Figure 17: Total Number of People in North America with Different Type of Cardiovascular Disease in 2018
  • Figure 18: North America DALYs of Ischemic Heart Disease (2014-2016 %)
  • Figure 19: North America DALYs of Chronic Kidney Disease (2014-2017 %)
  • Figure 20: North America DALYs of Chronic Obstructive Pulmonary Disease (2014-2017 %)
  • Figure 21: North America DALYs of Alzheimer Disease and Other Dementias (2014-2017 %)
  • Figure 22: North America DALYs of Diabetes Mellitus (2014-2017 %)
  • Figure 23: North America Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 24: Market Opportunity Chart of North America Biopharmaceutical CMO Market - By Country, By Value, 2025
  • Figure 25: North America Biopharmaceutical CMO Market, By Country, 2019, 2025
  • Figure 26: United States Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 27: United States Prevalence of Diabetes (Per 1,00,000 )2014-2017
  • Figure 28: United States Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2014-2017
  • Figure 29: Prevalence of Neurological Disorders in United States (2016, Million)
  • Figure 30: United States Prevalence of Cardiovascular Disorders (Per 1,00,000) 2014-2017
  • Figure 31: United States DALYs of Ischemic Heart Disease (2014-2017 %)
  • Figure 32: United States DALYs of Chronic Kidney Disease(2014-2017 %)
  • Figure 33: United States DALYs of Chronic Obstructive Pulmonary Disease(2014-2017 %)
  • Figure 34: United States DALYs of Alzheimer Disease and Other Dementias (2014-2017 %)
  • Figure 35: United States DALYs of Diabetes Mellitus (2014-2017 %)
  • Figure 36: United States Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 37: Europe Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 38: Number Of Deaths due to cancer in Europe, 2017
  • Figure 39: Share of older population 65 years and above as percentage of total population, 2017
  • Figure 40: Europe Prevalence of Gynecological (2014-2017, Million)
  • Figure 41: Europe Prevalence of Musculoskeletal Disorders (2014-2017, Million)
  • Figure 42: Total Number of People With Cardiovascular Disorders in Europe, By Type, 2017
  • Figure 43: Europe DALYs of Ischemic Heart Disease (2014-2017), in %
  • Figure 44: Europe DALYs of Chronic Kidney Disease(2014-2017)in %
  • Figure 45: Europe DALYs of Chronic Obstructive Pulmonary Disease(2014-2017 %)
  • Figure 46: Europe DALYs of Alzheimer Disease and Other Dementias (2014-2017 )in %
  • Figure 47: Europe DALYs of Diabetes Mellitus (2014-2017 )in %
  • Figure 48: Europe Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 49: Market Opportunity Chart of Europe Biopharmaceutical CMO Market - By Country, By Value, 2025
  • Figure 50: Europe Biopharmaceutical CMO Market, By Country, 2019, 2025
  • Figure 51: Germany Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 52: Germany DALYs of Ischemic Heart Disease (2014-2017), in %
  • Figure 53: Germany DALYs of Chronic Kidney Disease (2014-2017), in %
  • Figure 54: Germany DALYs of Chronic Obstructive Pulmonary Disease(2014-2017), in%
  • Figure 55: Germany DALYs of Alzheimer Disease and Other Dementias (2014-2017), %
  • Figure 56: Germany DALYs of Diabetes Mellitus (2014-2017), %
  • Figure 57: Germany Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 58: Switzerland Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 59: Switzerland Prevalence of Musculoskeletal Disorders (In Millions), 2014-2017
  • Figure 60: Total Number of People With Infectious Disorder in Switzerland (2014-2017), In thousands
  • Figure 61: Switzerland Prevalence of Neurological Disorders (2014-2017, Million)
  • Figure 62: Switzerland Prevalence of Cardiovascular Disorders, 2014-2017 (In Millions)
  • Figure 63: Switzerland Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 64: Denmark Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 65: Denmark Prevalence of Musculoskeletal Disorders (In Millions), 2014-2017
  • Figure 66: Total Number of People With Infectious Disorder in Denmark (2014-2017), In thousands
  • Figure 67: Denmark Prevalence of Neurological Disorders (2014-2017, Million)
  • Figure 68: Denmark Prevalence of Cardiovascular Disorders, 2014-2017 (In Millions)
  • Figure 69: Denmark Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 70: Asia Pacific Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 71: Asia, East Asia, Oceania , DALYs of Ischemic Heart Disease (2014-2017 %)
  • Figure 72: Asia, East Asia, Oceania DALYs of Chronic Kidney Disease(2014-2017 %)
  • Figure 73: Asia, East Asia, Oceania DALYs of Chronic Obstructive Pulmonary Disease(2014-2017 %)
  • Figure 74: Asia, East Asia, Oceania DALYs of Alzheimer Disease and Other Dementias (2014-2017 %)
  • Figure 75: Asia, East Asia, Oceania DALYs of Diabetes Mellitus (2014-2017 %)
  • Figure 76: Asia Pacific Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 77: Market Opportunity Chart of Asia Pacific Biopharmaceutical CMO Market - By Country, By Value, 2025
  • Figure 78: Asia Pacific Biopharmaceutical CMO Market, By Country, 2019, 2025
  • Figure 79: China Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 80: China DALYs of Ischemic Heart Disease (2014-2017 %)
  • Figure 81: China DALYs of Chronic Kidney Disease(2014-2017 %)
  • Figure 82: China DALYs of Chronic Obstructive Pulmonary Disease(2014-2017 %)
  • Figure 83: China DALYs of Alzheimer Disease and Other Dementias (2014-2017 %)
  • Figure 84: China DALYs of Diabetes Mellitus (2014-2017 %)
  • Figure 85: China Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 86: Japan Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 87: Japan DALYs of Ischemic Heart Disease (2014-2017 %)
  • Figure 88: Japan DALYs of Chronic Kidney Disease(2014-2017 %)
  • Figure 89: Japan DALYs of Chronic Obstructive Pulmonary Disease(2014-2017 %)
  • Figure 90: Japan DALYs of Alzheimer Disease and Other Dementias (2014-2017 %)
  • Figure 91: Japan DALYs of Diabetes Mellitus(2014-2017 %)
  • Figure 92: Japan Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 93: South Korea Biopharmaceutical CMO Market Size, By Value, 2015-2025 (USD Million)
  • Figure 94: South Korea Prevalence of Musculoskeletal Disorders (In Millions), 2014-2017
  • Figure 95: Total Number of People With Infectious Disorder in South Korea (2014-2017), In thousands
  • Figure 96: South Korea Prevalence of Neurological Disorders (2014-2017, Million)
  • Figure 97: South Korea Prevalence of Cardiovascular Disorders, 2014-2017 (In Millions)
  • Figure 98: South Korea Biopharmaceutical CMO Market - By Product Type, By Value, 2015-2025 (USD Million)
  • Figure 99: Market Attractiveness Chart of Global Biopharmaceutical CMO Market - By Product Type, 2025
  • Figure 100: Market Attractiveness Chart of Global Biopharmaceutical CMO Market - By Region, By Value, 2025
  • Figure 101: Market Share of Leading Global Biopharmaceutical CMO Companies, 2019 (In %)
  • Figure 102: Lonza, Net Sales, 2014-2017 (In Billion USD)
  • Figure 103: Boehringer Ingelheim, Net Sales, 2014-2016 (In Million USD)
  • Figure 104: Boehringer Ingelheim Sales by Region, 2016
  • Figure 105: Boehringer Ingelheim Sales by Segment, 2016Boehringer Ingelheim Sales by Segment, 2016
  • Figure 106: Samsung Biologics, Net Sales, 2014-2018 (In Million USD)
  • Figure 107: Samsung Biologics, Biomedicine manufacturing plants, 2017
  • Figure 108: Wuxi Biologics, Net Sales, 2014 - 2018 (In Million USD)
  • Figure 109: Wuxi Biologics, Sales by Region, 2018
  • Figure 110: Wuxi Biologics Sales by Region, 2017

List of Tables

  • Table A: A Brief Comparison Between Chemicals and Biologics
  • Table B: Number of people with diabetes worldwide and per region in 2017 and 2045, (20-79 years)
  • Table C: Diabetes Prevalence, By Country, in % of population ages 20 to 79 in 2017
目次

Executive Summary

Global Biopharmaceutical CMO Market was valued at USD 13296.29 million in the year 2019. Escalating number of patients suffering from various diseases with growing investment in the healthcare industry by government in major economies and increasing awareness among consumers regarding impact of various viruses on health, has been anticipated to infuse growth in the market for Biopharmaceutical CMO during the forecasting period of 2020-2025.

Under the product segment, Others is anticipated to witness a substantial market share owing to growing partnership among various pharmaceutical companies and leading CMOs which are helping in providing medicines, biologics delivery with advanced technology and efficient labour force backed with enhanced investment in expanding geographically, will be accelerating the Biopharmaceutical CMO market growth in the coming years.

Among the regions, Europe, followed by North America and Asia Pacific, will experience remarkable market share owing to presence of major countries including United Kingdom, Norway, Denmark, Switzerland that feature efficient healthcare system supported by ever growing number of patients. Rising need of developing medicine for many viruses coupled with growing mergers and acquisitions in the region between pharma companies and CMOs, will be propelling the Biopharmaceutical CMO market growth during the period of 2020-2025.

Scope of the Report

  • The report analyses Biopharmaceutical CMO market By Value.
  • The report analyses Biopharmaceutical CMO Market By Product Type (Microbial, and Others).
  • The Global Biopharmaceutical CMO Market has been analysed By Region (North America, Europe, and Asia Pacific) and By Country (United States, Germany, Switzerland, Denmark, China, Japan, South Korea).
  • The key insights of the report have been presented through the frameworks of Major mergers and acquisitions. Also, the attractiveness of the market has been presented By Region, and By Product Type. Additionally, the major opportunities, SWOT analysis, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Wuxi Biologics, Boehringer Ingelheim, Lonza, Samsung Biologics.
  • The report presents the analysis of Biopharmaceutical CMO market for the historical period of 2015-2019 and the forecast period of 2020-2025.

Key Target Audience

  • Biopharmaceutical CMO Vendors
  • Pharmaceutical Companies
  • Pharmaceutical Manufacturers
  • Consulting and Advisory Firms
  • Investment Banks and Equity Firms

Table of Contents

1. Research Methodology and Executive Summary

  • 1.1 Research Methodology
  • 1.2 Executive Summary

2. Strategic Recommendations

  • 2.1 Focus on Providing Quality and Reliability
  • 2.2 Focus on Investing in Internal Factors

3. Biopharmaceutical CMO Market : Product Outlook

4. Global Biopharmaceutical CMO Market: Sizing and Forecast

  • 4.1 Market Size, By Value, Year 2015-2025

5. Global Biopharmaceutical CMO Market Segmentation - By Product Type

  • 5.1 Competitive Scenario of Global Biopharmaceutical CMO Market: By Product Type
    • 5.1.1 Microbial - Market Size and Forecast (2015-2025)
    • 5.1.2 Others - Market Size and Forecast (2015-2025)

6. Global Biopharmaceutical CMO Market: Regional Analysis

  • 6.1 Competitive Scenario of Global Biopharmaceutical CMO Market : By Region

7. North America Biopharmaceutical CMO Market: Segmentation By Product Type (2015-2025)

  • 7.1 North America Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 7.2 Market Segmentation By Product Type (Microbial, and Others)
  • 7.3 North America Biopharmaceutical CMO Market: Country Analysis
  • 7.5 Market Opportunity Chart of North America Biopharmaceutical CMO Market - By Country, By Value, 2025
  • 7.6 Competitive Scenario of North America Biopharmaceutical CMO Market : By Country
  • 7.7 United States Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 7.8 United States Biopharmaceutical CMO Market Segmentation - By Product Type

8. Europe Biopharmaceutical CMO Market: Segmentation By Product Type (2015-2025)

  • 8.1 Europe Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 8.2 Market Segmentation By Product Type (Microbial, and Others)
  • 8.3 Europe Biopharmaceutical CMO Market: Country Analysis
  • 8.4 Market Opportunity Chart of Europe Biopharmaceutical CMO Market - By Country, By Value, 2025
  • 8.5 Competitive Scenario of Europe Biopharmaceutical CMO Market : By Country
  • 8.6 Germany Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 8.7 Germany Biopharmaceutical CMO Market Segmentation - By Product Type
  • 8.8 Switzerland Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 8.9 Switzerland Biopharmaceutical CMO Market Segmentation - By Product Type
  • 8.10 Denmark Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 8.11 Denmark Biopharmaceutical CMO Market Segmentation - By Product Type

9. Asia Pacific Biopharmaceutical CMO Market: Segmentation By Product Type (2015-2025)

  • 9.1 Asia Pacific Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 9.2 Market Segmentation By Product Type (Microbial, and Others)
  • 9.3 Asia Pacific Biopharmaceutical CMO Market: Country Analysis
  • 9.4 Market Opportunity Chart of Asia Pacific Biopharmaceutical CMO Market - By Country, By Value, 2025
  • 9.5 Competitive Scenario of Asia Pacific Biopharmaceutical CMO Market : By Country
  • 9.6 China Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 9.7 China Biopharmaceutical CMO Market Segmentation - By Product Type
  • 9.8 Japan Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 9.9 Japan Biopharmaceutical CMO Market Segmentation - By Product Type
  • 9.10 South Korea Biopharmaceutical CMO Market: Size and Forecast (2015-2025), By Value
  • 9.11 South Korea Biopharmaceutical CMO Market Segmentation - By Product Type

10. Global Biopharmaceutical CMO Market Dynamics

  • 10.1 Drivers
  • 10.2 Restraints
  • 10.3 Trends

11. Market Attractiveness

  • 11.1 Market Attractiveness Chart of Global Biopharmaceutical CMO Market - By Product Type, 2025
  • 11.3 Market Attractiveness Chart of Global Biopharmaceutical CMO Market - By Region, 2025

12. Strategic Analysis and Competitive Landscape

  • 12.1 SWOT Analysis
  • 12.2 Major Technological Innovations and Mergers & Acquisitions
  • 12.3 Market Share Analysis

13. Company Analysis

  • 13.1 Lonza
  • 13.2 Boehringer Ingelheim
  • 13.3 Samsung Biologics
  • 13.4 Wuxi Biologics
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.